EXHIBIT 10.25Consent to Assignment Agreement • August 9th, 2000 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations • California
EXHIBIT 10.24Assignment and Option Agreement • August 9th, 2000 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations • California
EXHIBIT 10.28 May 15, 2000 Tim Lynch Chief Financial Officer InterMune Pharmaceutical, Inc. 1710 Gilbreth Road, 3rd Floor Burlingame, CA 94010 Re: Additional Leased Space Dear Tim, The American Heart Association ("Landlord") proposes the following...Lease Agreement • August 9th, 2000 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations
The American Heart Association ("Landlord") proposes the following lease terms for the additional space desired by InterMune Pharmaceutical ("Tenant").
EXHIBIT 10.26Revenue Adjustment Agreement • August 9th, 2000 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations • California
VIA FACSIMILE ORIGINAL BY FEDEX Stephen N. Rosenfield, Esq. General Counsel InterMune Pharmaceuticals, Inc. 1710 Gilbreth Road Suite 301 Burlingame, CA 94010 RE: Return of rights to gamma interferon for treatment of infectious diseases in Japan Dear...License Agreement • August 9th, 2000 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations
In addition, in satisfaction of Section 2.1(h) of the License Agreement, Genentech hereby grants to InterMune an exclusive license under Genentech Patent Rights and under Genentech Knowhow to import, use, and sell any Licensed Protein Product that is a formulation of Immune Interferon in the treatment or prevention of any infectious diseases in Japan, subject to all terms and conditions of the License Agreement, including without limitation, the covenants not to sue provided in Section 2.1(g)(ii) and Genentech's right to use Licensed Protein Products solely for research purposes in the Field of Use in the Territory. Under Section 12.1 of the License Agreement, the grant of the foregoing license shall be effective as of the date of delivery of this notice to InterMune.
